Status: Available
Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
Trial details
Biological sex: AllType: Expanded AccessSponsor: Regeneron PharmaceuticalsUpdated: Mar 12, 2026
Eligibility criteria
Not listed